Compare Adaptive Biotechnologies Corp (ADPT) vs Fox Corp Class A (FOXA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fox Corp Class A — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Fox Corp Class A trades at $53.79 (market cap $21.80B). The key difference: Fox Corp Class A is far larger — about 6.5× Adaptive Biotechnologies Corp's market cap, and Fox Corp Class A pays a 1.02% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FOXA | |
|---|---|---|
Market Cap | $3.33B | $21.80B |
Sector | Health | Media |
52-Week High | $22.37 | $76.11 |
52-Week Low | $10.24 | $48.79 |
Enterprise Value | $3.19B | $25.77B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FOXA trades at $55.87, down 1.08% with bearish technical signals despite strong fundamentals. The company reported robust earnings with Q1 2026 EPS of $1.32 beating expectations by 29%, continuing a trend of quarterly beats. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. However, the stock faces headwinds from the recent $22B Roku acquisition announcement, which has raised leverage concerns and contributed to recent price weakness.
The outlook remains balanced with 50% analyst buy ratings and a $67.80 consensus target suggesting 21% upside potential. Key risks include integration challenges from the Roku acquisition and streaming competition, while opportunities lie in advertising growth from World Cup events and Tubi streaming momentum. Valuation appears reasonable with P/E of 14.7x and EV/EBITDA of 8.4x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
